{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', \"Modified Section 5.5.1 Treatment Administration to add 'placebo' after\", \"'dexamethasone' in the last sentence of the first paragraph\", 'Rationale: Modified to be consistent with the rest of the paragraph.', 'Modified Section 5.5.2.1 Packing and Labeling, Rovalpituzumab Tesirine and', 'Placebo to include updated Hazardous Drug packing and shipping standards.', 'Rationale: Added to clarify packaging and shipping requirements as per', 'applicable regulations.', 'Modified Section 5.5.2.2 Storage and Disposition of Blinded Investigational', 'Product(s) and Section 5.5.2.3 Preparation/Reconstitution of Dosage Form(s)', 'to note specific instructions for reconstituted and diluted IP will be found in an', 'outside document.', 'Rationale: Site awareness for a separate document that contains additional', 'information on IP storage and disposition.', 'Modified Section 5.5.4.1 Dosing to add fluid retention weight gain guidance.', 'Rationale: To instruct sites on cases of weight gain due to fluid retention.', 'Modified Table 5 to include:', 'Grade 2 pneumonitis', 'Reduce dose to 0.1 mg/kg', 'Discontinue Rova-T', 'Grade > 3 pneumonitis', 'Discontinue Rova-T', 'N/A', 'Addition of footnote b.', 'Rationale: Update dose modification guidelines to align with safety profile', 'for Rova-T as described in the IB v.7.', 'Modified Section 5.5.5.2 Blinding of Data for Independent Data Monitoring', 'Committee (IDMC) to update the change from an interim analysis to a futility', 'analysis.', 'Rationale: To align with the updated statistical plan.', 'Modified Section 5.5.7 Drug Accountability to update classification of Rova-T', 'as a dangerous good/hazardous material.', 'Rationale: Added to clarify classification as well as packaging and shipping', 'requirements as per applicable regulations.', '6']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Modified Section 6.1.1.3 to update guidance on capturing disease progression', 'and fatal events for AEs and SAEs in the CRF.', 'Rationale: To clarify on AE/SAE reporting regarding events due to disease', 'progression.', 'Modified Section 6.1.4 Deaths to add language about capturing these events in', 'the CRF.', 'Rationale: To provide guidance on capturing deaths during AE/SAE', 'reporting period in EDC.', \"Modified Section 6.1.5 Adverse Event Collection Period, to say 'All adverse\", 'events reported from the time of blinded investigational product administration', 'until 70 days following the last dose of blinded investigational product will be', \"collected, whether solicited or spontaneously reported by the subject.'\", 'Rationale: To clarify AE collection period from last dose of blinded IP.', 'Modified Section 6.1.6 Adverse Event Reporting to update the emergency', 'contact for the study and add updated language regarding SUSARs and', 'guidelines for the Reference Safety Information (RSI).', 'Rationale: Modification of the emergency contact for the study and current', 'information regarding SUSAR reporting.', 'Modified Section 6.1.8 Toxicity Management to add additional safety', 'guidance on serosal effusions, skin reactions, edema, and pneumonitis.', 'Rationale: Provide additional guidance to investigators and subjects for', 'awareness and guidance to align with IBv7.', 'Updated Section 7.0 Protocol Deviations-Primary and Alternate contact', 'information.', 'Rationale: To provide sites with current AbbVie contact information.', 'Modified Section 8.1.3 Efficacy Endpoints and Analyses to delete the first', 'sentence.', 'Rationale: Align with updated analysis plan as outlined above.', 'Updated Section 8.1.7 to Patient Reported Outcomes (PRO) and add the', \"following language, 'Physical functioning scale score in EORTC QLQ-C30 is\", \"the key secondary endpoint.'\", 'Rationale: Align with updated analysis plan as outlined above.', '7']\n\n###\n\n", "completion": "END"}